What is the Fiscal Year for Silexion Therapeutics Corp?

Headquarters

Ramat Gan, Israel

Industry

Biotechnology Research

Stock Symbol

SLXN

Website

Description

Silexion Therapeutics is a pioneering clinical-stage oncology-focused biotechnology company engaged in discovering and developing proprietary treatments for KRAS-driven cancers. The company’s platform technology is addressing difficult-to-treat solid tumors. Silexion’s lead product candidate, SIL-204, consists of locally administered small interfering RNAs, or siRNA, in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients combined with standard-of-care chemotherapy. SIL-204 is a siRNA product candidate following Phase 1 and Phase 2 clinical trials with Silexion’s first-generation siG12D-LODER, also referred to as LODER™. Results from the LODER™ Phase 2 clinical trial showed a trend for differences between treatment groups with the LODER arm suggesting an overall survival advantage of 9.3 months. Silexion commitment to Pushing the boundaries of therapeutic advancements in the field of oncology is focused on its second-generation microparticle delivery system, SIL-204 a newly formulated product that will improve clinical efficacy. Silexion plans to conduct a Phase 2/3 trial of SIL-204 in locally advanced pancreatic cancer patients that harbor the KRAS G12D and G12V mutations. Silexion Therapeutics Ltd. is headquartered in Israel and partnered with well known GMP compliant siRNA facility, LGC Axolabs group located in Petaluma California, and worldwide experts extended-release formulation facility, EVONIK Corporation located in Birmingham, Alabama to upscale manufacturing.